It was first characterised in preclinical research for its cytoprotective properties and has since accumulated over 100 peer-reviewed publications across gastroenterology, orthopaedics, and regenerative biology.1 What makes BPC-157 unusual is structural stability
Safety Data Sheet (SDS) How to Order Prescriptions from PBS Animal Health Smart, Simple and Safe Animal Pharmacy You Need Our Pharmacy Service is available in these states: Connecticut Florida Iowa Illinois Indiana Kentucky Maine Michigan Minnesota Missouri New Hampshire New York North Carolina North Dakota Ohio Pennsylvania South Carolina South Dakota Tennessee Vermont Virginia Wisconsin West Virginia We can receive a prescription through the three methods below
No injection guarantees energy, weight loss, immune protection, detoxification, or symptom relief
The total weekly dose remains 8mg, but the peak plasma concentration is lower, which reduces GI symptoms for many researchers
Full mechanism, beta-3 AR pathway detail, and research design guidance are available in the AOD-9604 5mg research guide on the Ascend Peptides UK blog
Professor Goldsteins research contributions include: Co-discovery and isolation of the thymosin family of peptides in the 1960s First clinical trials of thymosin preparations in immunodeficient children (1974) Characterization of thymosin beta-4s actin-binding and wound healing properties Development of therapeutic applications for tissue repair and regeneration Over 450 published scientific articles and 25+ patents related to thymosins Leadership in translating thymosin research toward clinical development Disclaimer: This spotlight is provided for educational purposes to acknowledge scientific contributions to BPC-157 and TB-500/thymosin beta-4 research